September 10, 2015 | PR.com
“We’re at a critical juncture in the development of this novel patient monitoring technology. During the next three months, we expect to speed up clinical prototype development and testing, further refine our business plan and showcase our achievements in front of leading investors,” said Noninvasix CEO Graham Randall, Ph.D. “Through the success of its first two classes, Health Wildcatters has proven to be an effective partner for startups, and we look forward to keeping pace.”
During the program, startups receive guidance from Health Wildcatters’ extensive network of investors and mentors. The program also provides access to office space and other strategic resources that help the companies grow.
Randall applied to the program after a chance meeting at an investor conference with Health Wildcatters’ CEO Hubert Zajicek, M.D. “He recognized the huge clinical need and encouraged us to apply,” said Randall.
“This technology is so far ahead of what’s currently used during labor and deliveries,” said Zajicek. “But as with many new technologies in the healthcare space, there can be a long road to commercialization. At Health Wildcatters, we work to shorten that road as much as possible, and look forward to helping Noninvasix bring their monitoring system to market so it can reach the patients that need it.”
Startups will focus on refining their pitches throughout the program, which culminates with a final “Pitch Day” in November. By focusing on the pitch, Health Wildcatters aims to set the teams up to successfully raise capital after the accelerator. They have been successful thus far, with the first two startup classes raising more than $10 million after participating in the program.
Nonivasix recently completed its third-generation clinical prototype, which has been tested in both fetuses and neonates in the delivery room and NICU at University of Texas Medical Branch in Galveston. The direct, real-time measurements will provide concrete, factual data that OB/GYNs can use to take informed action leading to better outcomes for both mom and baby.
About Noninvasix, Inc.
Using patented optoacoustic technology, Houston, Texas-based Noninvasix, Inc. has developed a solution for the safe, accurate and non-invasive monitoring of fetal welfare during labor and delivery. Noninvasix’s undertaking to significantly improve outcomes for mother and baby during labor, while reducing malpractice lawsuits and premiums, is backed by 15 years of optoacoustic research and $2 million in seed funding. For more information, visit www.noninvasix.com.
About Health Wildcatters
Health Wildcatters, a mentorship-driven seed accelerator, is improving healthcare by supporting entrepreneurs and companies that are developing innovative solutions for the industry. Health Wildcatters’ 12-week program offers healthcare-focused startups in the early stages of funding an initial seed investment, as well as access to mentors, advisors, office space and strategic resources needed to help the startups grow. Based in Dallas, Health Wildcatters was founded in 2013 and is currently accelerating its third class of startups. For more information visit healthwildcatters.com.